Ariosa Diagnostics Strengthens Management Team with Appointment of Thomas J. Musci, M.D. as Vice President, Clinical Development and Medical Affairs
SAN JOSE, Calif., May 1, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, is pleased to announce that Thomas J. Musci, M.D. will lead the clinical development and medical affairs of the company.
Dr. Musci is board-certified in Maternal-Fetal Medicine and Genetics and has had an extensive career in academics, private practice and industry. Recognized as a leader in clinical research on prenatal testing, Dr. Musci has served as chair of the Genetics Committee for the American Congress of Obstetricians and Gynecologists (ACOG), and is currently a member of the Professional Practice Guidelines Committee for the American College of Medical Genetics (ACMG). He was co-founder of San Francisco Perinatal Associates, Inc. and retains an appointment as Associate Clinical Professor with the Department of Obstetrics and Gynecology at University of California, San Francisco (UCSF). He recently held the position of Director of Clinical Affairs for Predictive Health with Novartis Diagnostics.
"Dr. Musci's addition to our team will help us maintain our clinical excellence standard with the Harmony™ Prenatal Test," said Ken Song, chief executive officer at Ariosa Diagnostics.
Dr. Musci graduated from Georgetown University School of Medicine in Washington, DC. After obtaining his medical doctorate, he completed his residency in Obstetrics and Gynecology and fellowships in Maternal-Fetal Medicine and Medical Genetics, as well as a post-doctoral fellowship in the Department of Biochemistry and Biophysics, all at UCSF.
Speaking of his new appointment, Dr. Musci stated, "The Harmony test developed by Ariosa represents a revolutionary advance in prenatal testing for common fetal trisomies and is supported by an impressive amount of clinical data. I look forward to helping educate providers, patients and other constituents on how the Harmony test can improve and streamline patient care during pregnancy."
About Ariosa Diagnostics
Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.
SOURCE Ariosa Diagnostics, Inc.